COVID-19 Impact on Oncology

Oncologists and hematologists are just a few of many healthcare providers that have had to quickly adjust their practice amid the COVID-19 pandemic to maintain quality care while also protecting patients and staff. Working with our partner, OncLive®, our latest Rapid Research Report offers insights on how the pandemic is affecting community
practices throughout the United States.

Telehealth is here to stay

8%

of HCPs used telehealth services prior to the pandemic

88%

have since adopted the practice

90%

say they’ll continue to do so

Future staff implications

90%

90% of practices are implementing virtual office visits—many utilizing PAs and NPs to handle telehealth calls.

Pharma may need to emphasize more remote detailing

61%

of practices do not anticipate engaging with sales reps in the same manner they did pre-pandemic.

COVID-19 testing is not universally available

Only about half of the staff members suspected of contracting the virus were able to get tested.
The pandemic has caused
oncologists to shift from infusions
to oral oncolytics for some patients.

Over half of the oncologists have shifted at least

10%

of their patients from infusions to oral oncolytics.

Oncology practice impact

doctors

About 80% of oncologists expect their practices to be back to “normal” within the next 12 months.

Early/accurate cancer diagnoses may have been impacted by restricted/limited testing and surgeries.

doctor with mask

Over half the oncologists have limited their surgeries, screenings, and testing as a result of the pandemic.

Brought to you by

HRA Research
HRA Research